Navigating the Complexities of Vaccination in Immunocompromised Patients: Balancing Protection and Risk
DOI:
https://doi.org/10.63501/t0v01743Keywords:
Vaccination, Immunocompromised Patinets, Complications of VaccinationAbstract
Vaccination remains one of the most effective tools in modern medicine, significantly reducing the burden of infectious diseases across populations. In immunocompromised individuals—such as those with primary immunodeficiencies, recipients of solid organ or stem cell transplants, patients with autoimmune conditions, and those undergoing chemotherapy or long-term immunosuppressive therapy—the stakes are even higher. These patients are often at increased risk of contracting vaccine-preventable diseases, which can result in more severe outcomes compared to the general population.
However, immunization in this vulnerable group is not straightforward. Immune dysregulation or suppression may lead to reduced immunogenicity, making vaccines less effective. Additionally, live attenuated vaccines may pose safety concerns, and there is ongoing debate about the timing, dosing, and selection of appropriate vaccines for these individuals. The balance between achieving sufficient immune protection and avoiding potential complications requires a nuanced, evidence-informed, and patient-specific approach.
This complexity underscores the importance of individualized vaccination strategies, ongoing research, and interdisciplinary collaboration between infectious disease specialists, immunologists, and primary care providers. As the landscape of immunomodulatory therapies continues to evolve, so too must our frameworks for ensuring that immunocompromised patients receive safe and effective immunization.
References
Akkaya, M., Kwak, K., & Pierce, S. K. (2020). B cell memory and plasma cell formation in the context of chronic antigen stimulation: Lessons from autoimmunity and infection. Frontiers in Immunology, 11, 621222.
Apostolidis, S. A., Kakara, M., Painter, M. M., et al. (2021). Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. Nature Medicine, 27(11), 1990-2001.
Bastard, P., Rosen, L. B., Zhang, Q., et al. (2020). Auto-antibodies against type I IFNs in patients with life-threatening COVID-19. Science, 370(6515), eabd4585.
Boyarsky, B. J., Werbel, W. A., Avery, R. K., et al. (2021). Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA, 325(17), 1784-1786.
Centers for Disease Control and Prevention (CDC). (2022). Interim clinical considerations for use of COVID-19 vaccines currently approved or authorized in the United States. Retrieved from https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
Diaz Granados, C. A., Dunning, A. J., Kimmel, M., et al. (2014). Efficacy of high-dose versus standard-dose influenza vaccine in older adults. New England Journal of Medicine, 371(7), 635-645.
O’Brien, M. P., Forleo-Neto, E., Musser, B. J., et al. (2022). Subcutaneous REGEN-COV antibody combination to prevent COVID-19. New England Journal of Medicine, 385(13), 1184-1195.
Papp, K. A., Haraoui, B., Kumar, D., et al. (2019). Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. Journal of Cutaneous Medicine and Surgery, 23(1), 50-57.
Socié, G., Ritz, J., & Reshef, R. (2021). Immunization strategies for patients undergoing hematopoietic stem cell transplantation. Blood Advances, 5(2), 321-330.
Downloads
Published
Issue
Section
License
This article is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, provided appropriate credit is given to the author(s) and the source. To view a copy of this license, visit: https://creativecommons.org/licenses/by/4.0